What Is the Four-Hit Model of IgA Nephropathy? Explained
At a Glance
The four-hit model explains how galactose-deficient IgA1 can trigger autoantibodies, form immune complexes, and deposit in kidney filters. These deposits may cause inflammation, blood or protein in the urine, and scarring, but the model alone cannot predict an individual's outcome.
The “four-hit model” is a leading framework that helps explain the biology of how IgA nephropathy develops. It is not a diagnostic test, but rather a useful step-by-step description of the biological process that can lead to kidney injury [1][2].
It is important to know that this disease is complex. Genetic, mucosal, and environmental factors also influence who develops it, and not everyone with the first “hit” will go on to develop kidney disease [3].
The Four Hits Explained
- Hit 1: Altered IgA Production. The immune system produces an antibody called Immunoglobulin A1 (IgA1) to help fight infections. In people with IgA nephropathy, the body produces an increased proportion of IgA1 molecules that are missing certain sugar molecules (galactose) in a specific area. This is called galactose-deficient IgA1 [4][1].
- Hit 2: Autoantibodies Target the Altered IgA. Some people’s immune systems produce autoantibodies—antibodies that mistakenly react to the person’s own tissues or molecules. In this case, these autoantibodies recognize the altered sugar pattern on the galactose-deficient IgA1 and bind to it [4][1].
- Hit 3: Immune Complexes Form. When the autoantibodies bind to the galactose-deficient IgA1 in the bloodstream, they link together to form clusters called circulating immune complexes [4][1].
- Hit 4: Deposition in the Kidneys. Some of these circulating immune complexes travel to the kidneys and deposit (build up) in the mesangium. The mesangium is the supportive tissue located between the delicate capillary loops of the kidney’s filtering units (glomeruli) [4][1].
How the Four Hits Can Lead to Kidney Damage
Once the immune complexes accumulate in the mesangium, they can trigger a cascade of events that injure the kidneys:
- Complement Activation and Inflammation: The deposited complexes can activate the complement system, a part of the immune system that promotes inflammation. This can cause the cells in the mesangium to become irritated, multiply, and release inflammatory chemicals [5][6].
- Hematuria (Blood in the Urine): Inflammation can damage the glomerular filtration barrier. When this barrier is damaged, red blood cells can leak into the urine. This is why many patients experience visible or microscopic blood in their urine, especially during active inflammation [7][8].
- Proteinuria (Protein in the Urine): Inflammation can also injure podocytes (specialized filtering cells) and alter the pressure in the filter, allowing essential proteins to leak into the urine [9][10]. Persistent protein in the urine is a central marker of ongoing kidney damage and a key predictor of long-term risk [11][12].
- Scarring (Sclerosis and Fibrosis): Over time, chronic immune-mediated injury can lead to permanent damage. This includes scarring within the filtering units (segmental glomerulosclerosis) and in the surrounding kidney tissue (tubulointerstitial fibrosis), which progressively reduces the kidneys’ ability to filter waste [10][13].
What This Means for Your Diagnosis and Care
While the four-hit model explains the disease process, doctors do not routinely test your blood or urine for these four hits to make decisions about your care. The model cannot by itself predict your individual outcome [1][2].
Instead, a diagnosis of IgA nephropathy is usually confirmed with a kidney biopsy when clinically appropriate. The biopsy allows doctors to look directly at the IgA deposits and assess the extent of active injury and permanent scarring (often summarized as an Oxford MEST-C score) [14][2].
To estimate your risk and guide treatment, your care team will monitor your kidney function (eGFR), blood pressure, and the amount of protein in your urine (usually measured as a protein-to-creatinine or albumin-to-creatinine ratio).
Safety Note: Contact your clinical team if you notice new visible blood in your urine, severe swelling, a substantial drop in urine output, or shortness of breath. While dark urine can happen during a respiratory infection, it is always best to report new symptoms to your doctor.
Common questions in this guide
What are the four hits in IgA nephropathy?
What does galactose-deficient IgA1 mean?
How can immune complexes cause kidney damage in IgA nephropathy?
Can doctors diagnose IgA nephropathy by testing for the four hits?
What tests help monitor the effects of IgA nephropathy?
When should I contact my care team about possible IgA nephropathy symptoms?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
The four hits
What does the four-hit model explain about kidney injury?
About testing
Is a kidney biopsy used to confirm IgA nephropathy?
Monitoring over time
How will my kidney function, blood pressure, and urine protein be monitored?
Related questions
Show more
Get notified when new evidence is published on Immunoglobulin A nephropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.
Suzuki H
Clinical and experimental nephrology 2019; (23(1)):26-31 doi:10.1007/s10157-018-1582-2.
PMID: 29740706 - 2
Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both?
Keskinis C, Moysidou E, Christodoulou M, et al.
Diagnostics (Basel, Switzerland) 2024; (14(5)) doi:10.3390/diagnostics14050512.
PMID: 38472984 - 3
TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.
Makita Y, Suzuki H, Kano T, et al.
Kidney international 2020; (97(2)):340-349 doi:10.1016/j.kint.2019.08.022.
PMID: 31748116 - 4
Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.
Knoppova B, Reily C, King RG, et al.
Journal of clinical medicine 2021; (10(19)) doi:10.3390/jcm10194501.
PMID: 34640530 - 5
The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.
Knoppova B, Reily C, Maillard N, et al.
Frontiers in immunology 2016; (7()):117 doi:10.3389/fimmu.2016.00117.
PMID: 27148252 - 6
Current Understanding of the Role of Complement in IgA Nephropathy.
Maillard N, Wyatt RJ, Julian BA, et al.
Journal of the American Society of Nephrology : JASN 2015; (26(7)):1503-12 doi:10.1681/ASN.2014101000.
PMID: 25694468 - 7
Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.
Floege J, Fervenza FC, Coppo R
Clinical kidney journal 2026; (19(2)):sfag003 doi:10.1093/ckj/sfag003.
PMID: 41704425 - 8
Role of Palatine Tonsil and Epipharyngeal Lymphoid Tissue in the Development of Glomerular Active Lesions (Glomerular vasculitis) in Immunoglobulin A Nephropathy.
Hotta O, Ieiri N, Nagai M, et al.
International journal of molecular sciences 2022; (23(2)) doi:10.3390/ijms23020727.
PMID: 35054911 - 9
IgA nephropathy.
Lai KN, Tang SC, Schena FP, et al.
Nature reviews. Disease primers 2016; (2()):16001 doi:10.1038/nrdp.2016.1.
PMID: 27189177 - 10
Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression.
Trimarchi H, Coppo R
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(8)):1280-1285 doi:10.1093/ndt/gfy413.
PMID: 30698804 - 11
Contemporary review of IgA nephropathy.
Filippone EJ, Gulati R, Farber JL
Frontiers in immunology 2024; (15()):1436923 doi:10.3389/fimmu.2024.1436923.
PMID: 39188719 - 12
A cross-sectional study in patients with IgA nephropathy of correlations between clinical data and pathological findings at the time of renal biopsy: a Japanese prospective cohort study.
Kamano C, Shimizu A, Joh K, et al.
Clinical and experimental nephrology 2021; (25(5)):509-521 doi:10.1007/s10157-021-02022-x.
PMID: 33595730 - 13
Treatment of IgA Nephropathy: A Rapidly Evolving Field.
El Karoui K, Fervenza FC, De Vriese AS
Journal of the American Society of Nephrology : JASN 2024; (35(1)):103-116 doi:10.1681/ASN.0000000000000242.
PMID: 37772889 - 14
The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
Rizk DV, Maillard N, Julian BA, et al.
Frontiers in immunology 2019; (10()):504 doi:10.3389/fimmu.2019.00504.
PMID: 30941137
This page explains the four-hit model of IgA nephropathy for informational purposes only and does not constitute medical advice. Your nephrology team should interpret your biopsy, test results, and symptoms.